Clinical trials: Epithelial Neoplasms, Malignant
Otitis Media, Otitis Media With Effusion After Nasopharyngeal Carcinoma
Intranasal Corticosteroid Spray for Preventing Otitis Media With Effusion After Radiotherapy in Nasopharyngeal Carcinoma
This study focuses on a common side effect experienced by many patients after radiation therapy for nasopharyngeal cancer, which is a type of head and neck cancer.
- Conditions
- Otitis Media, Otitis Media With Effusion After Nasopharyngeal Carcinoma, Radiotherapy Side Effects, Radiotherapy Side Effect
- Trial name
- NCT07189572
- Testing
- Triamcinolone Acetonide
- Volunteers
- 168 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer
PET Imaging of Ovarian Carcinoma With 18F-FSPG
This clinical trial studies positron emission tomography (PET) imaging utilizing 18F-FSPG [(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid], a glutamic acid derivative, to image patients with ovarian cancer before undergoing surgery…
- Conditions
- Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer
- Trial name
- NCT02872519
- Testing
- (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG), Positron Emission Tomography, Laboratory Biomarker Analysis
- Sponsor
- Vanderbilt-Ingram Cancer Center
Hepatocellular Carcinoma (HCC), Cirrhosis
Biannual Screening for HCC Offered to Patients With Cirrhosis. Introducing Surveillance for Hepatocellular Carcinoma (HCC) in the Central Denmark Region Using Ultrasound and Alpha-Fetoprotein to Reduce HCC-Related Mortality in Patients With Compensated Non-Viral Cirrhosis
This study aims to investigate whether repeated 6-monthly screening for hepatocellular carcinoma (HCC) - called "HCC surveillance" - offered to selected patients with chronic liver disease can reduce HCC-related mortality by…
- Trial name
- BISHOP (NCT07469319)
- Testing
- Ultrasound of the liver and blood sample for alpha-fetoprotein
- Where
- 6 sites in Denmark
- Volunteers
- 617 people
- Sponsor
- University of Aarhus
Non-small Cell Lung Cancer
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)
Stage IIIA non-small cell lung cancers comprising a mediastinal ganglionic invasion N2 account for 20 to 30% of the NSCLCs. They are almost always potentially resectable, but the results obtained by surgery alone or surgery…
- Trial name
- NCT00198367
- Testing
- Cisplatin-Gemzar, Cisplatin-Navelbine-Radiotherapy, Carboplatin-Taxol-Radiotherapy
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Carcinoma, Endometrial Adenocarcinoma
PEN-866 in Patients With Advanced Solid Malignancies
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
- Conditions
- Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus
- Trial name
- NCT03221400
- Testing
- PEN-866 Sodium, fluorouracil, Folinic acid
- Where
- 16 sites in United States
- Volunteers
- 340 people
- Sponsor
- Tarveda Therapeutics
Non-small-cell Lung Cancer
Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions
Various driver gene mutations have been identified in lung cancer. Among them, human epidermal growth factor 2 (HER2) was identified in approximately 2% of non-small-cell lung cancers.
- Trial name
- NCT04382300
- Testing
- pyrotinib combined with thalidomide
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Shanghai Chest Hospital
Oral Cavity Squamous Cell Carcinoma
Study Comparing Limited and Extensive Neck Surgery in Oral Cancer Patients With Neck Spread
Oral cavity squamous cell carcinoma (OCSCC) frequently metastasizes to cervical lymph nodes, and the extent of neck dissection remains an area of ongoing debate in patients with clinically node-positive (cN1) disease.
- Trial name
- ExtentN1 (NCT07717307)
- Testing
- Selective Neck Dissection (Levels I-IV), Modified Neck Dissection (Levels I-V)
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Kolhapur Cancer Centre - Cancer Centers of America
NSCLC Stage IV, Brain Metastases
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.
- Conditions
- NSCLC Stage IV, Brain Metastases, Immunotherapy
- Trial name
- NCT04291092
- Testing
- Immunotherapy, WBRT, Chemotherapy
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Zhejiang Cancer Hospital
Esthesioneuroblastoma, Olfactory
Esthesioneuroblastoma: Outcomes After Treatment
The purpose of this study is to collect and organize data into a repository to gather relevant information for future research from patients diagnosed with a rare malignant sinonasal cancer called esthesioneuroblastoma (ENB) and…
- Trial name
- ENB (NCT02580136)
- Where
- United States
- Sponsor
- Ricardo L. Carrau, MD
Ovarian Epithelial Cancer
Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer
Ovarian cancer is among the top five primary causes of cancer-related mortality in women. Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis.
- Trial name
- NCT06404671
- Testing
- Delayed interval cytoreductive surgery (DICS), Early interval cytoreductive surgery (EICS)
- Where
- Egypt
- Volunteers
- 250 people
- Sponsor
- Alexandria University
Glioblastoma
Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma
The purpose of this study is to determine the effect of Lixumistat in patients with newly diagnosed Glioblastoma.
- Trial name
- LixuWoO (NCT07884344)
- Testing
- Lixumistat - Cohort 1, Lixumistat - Cohort 2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Macarena De La Fuente, MD
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, and gemcitabine, work in different ways to stop the growth of tumor…
- Trial name
- NCT00623064
- Testing
- cisplatin, gemcitabine hydrochloride, lapatinib ditosylate
- Where
- Denmark
- Volunteers
- 18 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Von Hippel-Lindau Syndrome, Renal Cell Carcinoma
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
The goal of this clinical research study is to learn if sunitinib malate (SU011248) can help to control VHL. The safety of this drug will also be studied.
- Conditions
- Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
- Trial name
- NCT00330564
- Testing
- SU011248
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Glioma, Malignant
An Integrated Radio-immunological Approach
The most aggressive primary brain tumors in adults, glioblastomas, are characterized by a profound local and systemic immune suppression.
- Trial name
- IMMUNO-IMAGING (NCT05267509)
- Where
- 2 sites in Italy
- Volunteers
- 31 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Liver Cirrhosis, Hepatocellular Carcinoma
Relevance of Sarcopenia in Advanced Liver Disease
Patients with established liver cirrhosis, or end-stage liver disease (ESLD), are at high risk of developing liver cancer (hepatic carcinoma; HCC), portal hypertension, and sarcopenia, all which lead to significant morbidity and…
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Sarcopenia, Portal Hypertension
- Trial name
- ACCESS-ESLD (NCT05502198)
- Where
- 3 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Linkoeping University
Oral Mucositis, Quality of Life
Effect of Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules on Oral Mucositis in Nasopharyngeal Carcinoma Patients Receiving Radiotherapy.
Effect of Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules on Oral Mucositis in Nasopharyngeal Carcinoma Patients Receiving Radiotherapy.
- Trial name
- NCT03112837
- Testing
- Lactobacillus, Bifidobacterium and Enterococcus
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jiangxi Provincial Cancer Hospital
Thymoma, Stomach Neoplasms
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Background: Malignant mesothelioma is a malignancy arising from the mesothelial cells of the pleura, peritoneum, pericardium, or tunica vaginalis. Mesothelioma accounts for 0.10% of deaths annually in the United States.
- Conditions
- Thymoma, Stomach Neoplasms, Pancreatic Neoplasms, Mesothelioma
- Trial name
- NCT01950572
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Neuroendocrine Carcinoma
Multi-omics Study of Cervical Neuroendocrine Carcinoma
This is a retrospective study using archived tumor tissue and medical records from patients with cervical neuroendocrine carcinoma treated at Peking Union Medical College Hospital since January 1, 2015.
- Trial name
- NCT07879339
- Testing
- Multi-omics profiling of archived tumor tissue (observational)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Peking Union Medical College Hospital
Epithelial Ovarian Cancer, Relapse
Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse
Assessing the safety and efficacy of the bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination in patient with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at…
- Trial name
- BOLD (NCT04015739)
- Testing
- Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination
- Where
- 9 sites in France
- Volunteers
- 74 people
- Sponsor
- ARCAGY/ GINECO GROUP
In Escalation: All Patients With Solid Tumors and Lymphoma, In Expansion: Melanoma, Non-small Cell Lung Cancer
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
The purpose of this phase I/Ib study was to determine the safety profile of NIZ985 (new formulation), and if it could be safely combined with spartalizumab or tislelizumab and to determine the appropriate dose and schedule for…
- Trial name
- NCT04261439
- Testing
- NIZ985, Spartalizumab, Tislelizumab
- Where
- 9 sites in United States, Belgium and 5 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.